Dendritic cell immunotherapy for the treatment of neoplastic disease

26Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

It has long been promised that dendritic cell immunotherapy would revolutionize the treatment of neoplastic disease. Now, more than 10 years since the publication of the first clinical data, a firmer understanding of immunology and dendritic cell biology is beginning to produce interesting clinical results. This article reviews the clinical trials that established many of the concepts with which today's investigators are achieving improved results, discusses issues in dendritic cell immunotherapy that are currently unresolved, and offers a perspective on the strategies that the authors believe will be important for the design of future vaccine trials, including the use of Toll-like receptor agonists as maturation agents, the accessory use of the plasmacytoid dendritic cell subset, and the maximization of T-cell help. © 2006 American Society for Blood and Marrow Transplantation.

Cite

CITATION STYLE

APA

Decker, W. K., Xing, D., & Shpall, E. J. (2006, February). Dendritic cell immunotherapy for the treatment of neoplastic disease. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2005.09.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free